Europe
Scientists from the U.K. may have identified several more environmental causes for cancer after evaluating genetic data of over 12,000 cancer patients from the NHS files.
The initial program will focus on one degrader combined with multiple proprietary E3 ligase platforms and use VantAI’s geometric deep learning platform.
British employees of pharma giant GlaxoSmithKline (GSK) have voted to strike against the company’s recent pay raise. The employees are backed by British labor union Unite.
AbbVie, Novartis, Pfizer and other biopharma companies are ramping up support to Ukraine in the face of the continuing Russian invasion.
ProQR Therapeutics, which is developing RNA therapies for genetic eye diseases, announced Wednesday that it will be restructuring and laying off 30% of its staff.
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
Companies working on cell therapies got most of the funding in the life sciences venture capital world this week. For that and more, continue reading.
Boehringer Ingelheim made a splash on Tuesday, announcing its intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.
Oculis has identified pressing unmet therapeutic needs and innovative, differentiated approaches to meet those needs.
The landmark Human Challenge Programme deliberately exposed 36 young and healthy participants ages 18 to 30 with no immunity to the SARS-CoV-2 virus for 14 days.
PRESS RELEASES